Project Grant R16GM153601
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded $238,685 to the University of California, San Francisco under the Drug Use and Addiction Research Programs (CFDA 93.279) Project Grant mechanism for research examining sex-dependent control of nociception by meningeal regulatory T cells. The award, effective August 1, 2025, through July 31, 2027, supports a structured research initiative investigating the biological mechanisms underlying sex...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to define the systemic mechanisms by which adipose (fat) tissue communicates with the knee joint to drive the development of osteoarthritis (OA). The $1,476,001 award to the Regents of the University of California, San Francisco will fund a comprehensive investigation of three potential interorgan crosstalk pathways: signaling through...
- This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop computational tools to accurately predict and interpret different patterns of knee pain in patients with osteoarthritis. The $348,680 award, with a period of performance from Sep 26, 2024 to Aug 31, 2026, will enable researchers at the University of Arizona to: 1) Adapt a...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $774,930.00 to the Regents of the University of Minnesota to develop and validate a mouse model of intervertebral disc degeneration-induced low back pain. The goal is to create a clinically representative preclinical model that can facilitate the discovery of novel non-addictive analgesics for the treatment of discogenic low...
- Federal Project Grant Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $421,437 to the Regents of the University of Minnesota on July 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The two-year project, extending through June 30, 2027, supports basic neuroscience research investigating sex-dependent functions of spinal dopamine 1 receptors (DRD1) in neuropathic pain models. The research...
- This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...
- This $408,000 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to provide a comprehensive EEG profile of the cortical activity underlying the cognitive processing of the sensory-discriminative and affective-motivational dimensions of osteoarthritis knee pain. The research, conducted by Tarleton State University,...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $452,437 to Tufts University School of Medicine to investigate the role of mast cell heterogeneity in the pathogenesis of osteoarthritis (OA). The objective is to uncover the genetic basis and functions of different mast cell subtypes in the OA synovium using advanced proteomics and single-cell RNA sequencing technologies, as well as testing them in a mouse model. The research aims to...
- Federal Project Grant Award Summary Duquesne University received a $517,494 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective July 1, 2025, through June 30, 2028. The award funds research to identify differentially expressed RNA splice isoforms of the transcription factor ATF3 (Activating Transcription Factor 3) that account for sex-specific...
- This $764,659 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to investigate the mechanisms underlying neuropathic spontaneous pain. The key objectives are to characterize the role of local vascular movement in triggering neuropathic spontaneous pain, determine how mechanoreceptors in sensory neurons contribute...
MECHANISMS UNDERLYING SEX DIFFERENCES IN EMERGENCE OF ADVANCED OSTEOARTHRITIS PAIN - ABSTRACT OA PAIN IS HETEROGENEOUS WITH DISTINCT MECHANISMS ACROSS PAIN PHENOTYPES THAT ARE POORLY UNDERSTOOD AND THAT LIKELY UNDERLIE THE VARIABILITY IN THERAPEUTIC EFFICACY ACROSS OA PAIN PATIENTS. MANY OA PATIENTS REPORT MID- STAGE OA PAIN THAT OCCURS DURING JOINT USE AND DISSIPATES DURING REST. OTHERS DEVELOP ADVANCED OA PAIN CHARACTERIZED BY PERSISTENT JOINT PAIN THAT DOES NOT DISSIPATE DURING REST AND THAT IS RESISTANT TO CURRENT TREATMENTS. FEMALES HAVE A HIGHER INCIDENCE OF OA PAIN AND REPORT MORE SEVERE PAIN COMPARED TO MALES. THIS GRANT APPLICATION USES AN INNOVATIVE MOUSE MODEL OF MID- AND ADVANCED OA PAIN THAT ALLOWS ANALYSIS OF MECHANISMS UNDERLYING THE TRANSITION BETWEEN MID-STAGE AND ADVANCED OA PAIN. FEMALE MICE DEVELOP ADVANCED OA PAIN WITH LESS JOINT DAMAGE COMPARED TO MALES ALLOWING ANALYSIS OF SEX DIFFERENCES THAT UNDERLIE ENHANCED SUSCEPTIBILITY FOR FEMALES TO DEVELOP ADVANCED OA PAIN COMPARED TO MALES. THE PROPOSED STUDIES WILL INVESTIGATE PATHOLOGICAL CHANGES IN INNERVATION OF THE JOINT AND ADJACENT MUSCLE BY COMPARING CONTROLS TO MID-STAGE AND ADVANCED OA PAIN. THE SPECIFIC AIMS WILL EXPLORE THE HYPOTHESIS THAT MICE WITH ADVANCED OA HAVE SENSORY NERVE SPROUTING INTO JOINT TISSUES AND ADJACENT MUSCLE AS WELL AS SENSORY NERVE DAMAGE AND THAT FEMALES DEVELOP NERVE SPROUTING AND NERVE INJURY IN THE CONTEXT OF LESS JOINT TISSUE DAMAGE COMPARED TO MALES. AIM 1 WILL DETERMINE PATHOLOGICAL SPROUTING OF SENSORY NERVES IN THE KNEE JOINT AND SURROUNDING MUSCLE OF MALE AND FEMALE MICE WITH MID-STAGE AND ADVANCED OA PAIN. THIS AIM WILL EXAMINE WHETHER MALES AND FEMALES WITH ADVANCED OA DEVELOP PATHOLOGICAL SPROUTING OF SMALL DIAMETER CGRP POSITIVE FIBERS AND NF-200 POSITIVE MYELINATED FIBERS INTO JOINT TISSUES AND ADJACENT MUSCLE, AND WHETHER FEMALES WITH ADVANCED OA PAIN SHOW PATHOLOGICAL SPROUTING IN THE CONTEXT OF LESS JOINT TISSUE DAMAGE. AIM 2 WILL DETERMINE POTENTIAL DIFFERENCES IN AXONAL NERVE INJURY THROUGH INDUCTION OF ATF3 IN SENSORY NEURON CELL BODIES OF MALE AND FEMALE MICE WITH MID-STAGE AND ADVANCED OA PAIN. RETROGRADE LABELING FROM THE KNEE JOINT OR TIBIALIS ANTERIOR MUSCLE WILL BE USED TO EXAMINE WHETHER THERE ARE DIFFERENCES IN ATF3 WITHIN SENSORY NEURONS INNERVATING THE JOINT COMPARED TO THE ADJACENT MUSCLE. CO-LABELING OF ATF3 WITH CGRP AND NF200 WILL BE USED TO ANALYZE WHETHER THERE ARE DIFFERENCES IN NERVE INJURY ACROSS THE DIFFERENT POPULATIONS OF SENSORY FIBERS. THESE TECHNIQUES WILL ELUCIDATE WHETHER NERVE INJURY OCCURS SPECIFICALLY IN THE CONTEXT OF ADVANCED OA PAIN AND WHETHER IT IS OBSERVED IN FEMALES WITH LESS JOINT PATHOLOGY COMPARED TO MALES. IMPROVED UNDERSTANDING OF THE PATHOPHYSIOLOGICAL CHANGES WITHIN THE JOINT THAT DIFFER BETWEEN MID-STAGE AND ADVANCED OA PAIN IS A CRITICAL STEP IN IMPROVING PAIN MANAGEMENT ACROSS THIS HETEROGENEOUS PAIN CONDITION. DIRECT ANALYSIS OF SEXUAL DIMORPHISM IN THESE CHANGES WILL PROVIDE INSIGHTS INTO POTENTIAL INCREASE SUSCEPTIBILITY FOR FEMALES TO DEVELOP NEUROPATHIC PAIN AND REQUIRE DIFFERENT THERAPEUTIC TREATMENT STRATEGIES COMPARED TO MALES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $142.0k | 7/15/25 | ||
| Not listed | $142.0k | 7/29/24 |